
Daily Brief Credit: H&H International – Earnings Flash – FY 2022 Results – Lucror Analytics and more
In today’s briefing:
- H&H International – Earnings Flash – FY 2022 Results – Lucror Analytics
- Europe HY Trade Book – March 2023 – Lucror Analytics
- Morning Views Asia:
- Quest Diagnostics Incorporated: Detailed Credit Analysis & Financial Strength Evaluation Report
- Zimmer Biomet Holdings Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report
H&H International – Earnings Flash – FY 2022 Results – Lucror Analytics
H&H International has released reasonable FY 2022 results, despite the challenging macro economy and operating conditions during the year. Revenue rose more than 10% y-o-y to c. CNY 12.8 bn, mainly due to the full-year inclusion of Zesty Paws in the US. The gross profit margin contracted 2.5 ppts to 60.3%. Debt/EBITDA remained elevated at 5.7x as at FYE 2022. Liquidity is sound, with a cash balance of over CNY 2 bn and short-term debt of only CNY 1 bn.
The company aims to reduce net leverage to below 2.0x within three years. In our view, this plan is aggressive albeit attainable.
Europe HY Trade Book – March 2023 – Lucror Analytics
The Europe HY Trade Book for March 2023 includes high-conviction trade ideas drawn from our European HY coverage universe, along with relative-value scatter plots and tables by industry.
Morning Views Asia:
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.
Quest Diagnostics Incorporated: Detailed Credit Analysis & Financial Strength Evaluation Report
- Quest Diagnostics Incorporated is a well-known provider of diagnostic information services.
- The company produced significant double-digit growth in prenatal genetics and pharmaceutical services for sophisticated diagnostics.
- Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.
Zimmer Biomet Holdings Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report
- Zimmer Biomet Holdings is a global medical technology giant.
- The management has been seeing positive comps across 2022 and saw good growth in major joints, with their entire global hip and knee business expanding well.
- Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars







